Hal W. Hirte

Hal Hirte is a Medical Oncologist at the Juravinski Cancer Centre in Hamilton, Ontario, and Professor at McMaster University. He is a clinician-scientist with a long track record in gynecologic oncology clinical trials and a particular interest in novel therapeutic targets and biomarkers in ovarian cancer. His research has contributed to the evaluation of CA-125 kinetics as a surrogate endpoint for monitoring treatment response and disease progression in clinical trials, addressing longstanding controversies about the role of CA-125 in response assessment. Hirte has been a principal investigator and participant in numerous early- and late-phase clinical trials in recurrent ovarian cancer, including studies of serine-threonine kinase inhibitors, antiangiogenic agents, and novel cytotoxic agents. His clinical research has helped define activity signals and tolerability profiles for emerging therapeutics evaluated through the NCIC Clinical Trials Group (now the Canadian Cancer Trials Group, CCTG) and cooperative international consortia. At the Juravinski Cancer Centre, Hirte has contributed to building a robust gynecologic oncology clinical trials infrastructure serving Ontario and Canada. He has been an advocate for patient access to experimental therapeutics and has participated in consensus efforts to standardize response assessment in ovarian cancer clinical trials. His contributions span biomarker science, early drug development, and translational oncology in gynecologic malignancies.